Editorial |

Nitric Oxide and Symptom Reduction in Schizophrenia

Joseph T. Coyle, MD1
[+] Author Affiliations
1Department of Psychiatry, Harvard Medical School, Belmont, Massachusetts
JAMA Psychiatry. 2013;70(7):664-665. doi:10.1001/jamapsychiatry.2013.210.
Text Size: A A A
Published online


In this issue of the journal, Hallak et al1 report results from a placebo-controlled clinical trial showing that infusion of sodium nitroprusside causes a rapid and persistent reduction of symptoms in patients with schizophrenia who have been symptomatically stabilized with antipsychotic medications. The peer reviewers of the manuscript concurred that the study pointed to a potentially new avenue for pharmacologic intervention in schizophrenia, although they recognized that the small number of patients studied was a serious limitation. It is true that the field is littered with small trials with robust outcomes that ultimately are not replicated. However, the rationale for the study was tethered to an increasingly compelling body of evidence from drug challenges, postmortem analysis, and gene association studies that hypofunction of the N-methyl-d-aspartate (NMDA) receptor, a glutamate receptor subtype that mediates neural plasticity, is a core feature of schizophrenia.2 In particular, NMDA receptor hypofunction appears to be particularly relevant to negative symptoms and cognitive impairments in schizophrenia.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 1

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles